Janus Henderson Group PLC grew its stake in DBV Technologies SA – (NASDAQ:DBVT) by 10.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,797,789 shares of the company’s stock after acquiring an additional 257,210 shares during the quarter. Janus Henderson Group PLC owned about 5.67% of DBV Technologies worth $118,738,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Granite Point Capital Management L.P. acquired a new stake in shares of DBV Technologies in the 3rd quarter worth $1,698,000. Citadel Advisors LLC acquired a new stake in shares of DBV Technologies during the 3rd quarter worth about $7,794,000. Dynamic Technology Lab Private Ltd increased its position in shares of DBV Technologies by 87.6% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock worth $495,000 after purchasing an additional 5,441 shares during the last quarter. Commonwealth Equity Services Inc acquired a new stake in shares of DBV Technologies during the 3rd quarter worth about $233,000. Finally, Quantbot Technologies LP acquired a new stake in shares of DBV Technologies during the 3rd quarter worth about $146,000. 46.94% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on DBVT. BidaskClub downgraded DBV Technologies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. Societe Generale downgraded DBV Technologies from a “buy” rating to a “sell” rating in a research report on Tuesday, October 24th. Zacks Investment Research downgraded DBV Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 29th. Jefferies Group reissued a “buy” rating on shares of DBV Technologies in a research report on Thursday, August 31st. Finally, JMP Securities began coverage on DBV Technologies in a research report on Friday, November 17th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $49.63.

DBV Technologies SA – (NASDAQ:DBVT) opened at $21.41 on Thursday. DBV Technologies SA – has a twelve month low of $20.58 and a twelve month high of $50.57.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/12/14/janus-henderson-group-plc-buys-257210-shares-of-dbv-technologies-sa-dbvt.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Institutional Ownership by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.